DNA-based breast cancer testing is taking a step forward. Illumina in San Diego, which sells next-generation sequencing (NGS) technology, announced a partnership with Agendia in Irvine, Calif., to develop in vitro diagnostic tests for oncology. Agendia offers proprietary breast cancer tests. The companies expect Agendia’s MammaPrint test to become the first decentralized, NGS-based breast cancer risk …
January 31, 2022 Intelligence: Late-Breaking Lab News Read More »
